Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00015106|
Recruitment Status : Completed
First Posted : April 18, 2001
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cocaine-Related Disorders||Drug: Lamotrigine||Phase 2|
Considerable progress in preclinical research has provided a basis for hypothesis driven clinical trials in cocaine dependence. A greater mechanistic understanding of both cocaine and many clinically approved medications has led to the identification of many promising medications for the treatment of cocaine dependence.
For this reason NIDA has developed a CREST (Clinical Rapid Evaluation Screening Trial) protocol to provide a needed incremental medication screening step between preclinical research and full blown expensive Phase III pivotal trials. While patients receive manual based psychotherapy, three medications are screened compared to unmatched placebo in an eight-week, 60-subject, four cell design trial. Other important features of the CREST protocol include collecting baseline measurements over a two week period and analyzing primary outcome measures (quantitative urine toxicology and clinical global improvement scales) in terms of a composite score of overall individual patient improvement.
The three medications being evaluated in this trial include reserpine, gabapentin and lamotrigine. Reserpine is being screened because of its well-known preclinical ability to functionally antagonize cocaine (by depleting neurochemicals elevated by cocaine). Gabapentin and lamotrigine are hypothesized to interfere with glutamatergic cocaine sensitization/kindling mechanisms relevant to addiction.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo|
|Study Start Date :||November 1997|
|Actual Primary Completion Date :||January 1999|
|Actual Study Completion Date :||February 1999|
- Urine toxicology for cocaine
- Adverse events
- Clinical improvement
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00015106
|United States, Ohio|
|Cincinnati, Ohio, United States, 45220|
|Principal Investigator:||Eugene Somoza, M.D., Ph.D.||Cincinnati MDRU|